Skip to main content
Fig. 2 | BMC Biotechnology

Fig. 2

From: Isolation of nanomolar scFvs of non-human primate origin, cross-neutralizing botulinum neurotoxins A1 and A2 by targeting their heavy chain

Fig. 2

Neutralization of BoNT/A1 and BoNT/A2 by high concentration of scFvs in the mouse phrenic nerve-hemidiaphragm assay. a Neutralization of purified-BoNT/A1 holotoxin (20 LD50.ml−1) with A1HC17, A1HC38 or A1HC45 at a single high concentration. b Neutralization of complexed-BoNT/A2 (10 LD50.ml−1) with A1HC17, A1HC38 or A1HC45 at a single high concentration. BoNT/A1 and BoNT/A2 were premixed with 27, 20, 15, 12 or 5 μg.mL−1 of A1HC17, A1HC38 or A1HC45 or with the commercial polyvalent F(ab’)2 antitoxin (activity of 20 mIU.mL−1 against BoNT/A). The toxins alone were used as controls to determine the time required to observed a 50 % decrease in the twitch height. No significant neutralization was observed with an irrelevant scFv directed against the ricin toxin (referred as “negative control”), tested at a single concentration of 9 μg.mL−1 in all experiments. The experiments were run until a decrease of at least 50 % in the twitch height was observed, until the phrenic nerve hemidiaphragm preparation was no longer viable or until no more twitch was detected. Control tissues, not exposed to the toxin were included to demonstrate stability of recordings (referred as “No toxin”)

Back to article page